Stellar Biotechnologies Inc. (SBOT) and Anavex Life Sciences Corp. (NASDAQ:AVXL) Comparison side by side

Stellar Biotechnologies Inc. (NASDAQ:SBOT) and Anavex Life Sciences Corp. (NASDAQ:AVXL) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Stellar Biotechnologies Inc. N/A 24.65 5.04M -2.42 0.00
Anavex Life Sciences Corp. N/A 0.00 20.73M -0.38 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Stellar Biotechnologies Inc. and Anavex Life Sciences Corp.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Stellar Biotechnologies Inc. and Anavex Life Sciences Corp.

Net Margins Return on Equity Return on Assets
Stellar Biotechnologies Inc. 0.00% -58.5% -55.2%
Anavex Life Sciences Corp. 0.00% -70.2% -61.8%

Risk & Volatility

A 0.42 beta indicates that Stellar Biotechnologies Inc. is 58.00% less volatile compared to Standard & Poor’s 500. Competitively, Anavex Life Sciences Corp.’s 85.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 1.85 beta.

Liquidity

Stellar Biotechnologies Inc. has a Current Ratio of 21.6 and a Quick Ratio of 21.1. Competitively, Anavex Life Sciences Corp.’s Current Ratio is 8.3 and has 8.3 Quick Ratio. Stellar Biotechnologies Inc.’s better ability to pay short and long-term obligations than Anavex Life Sciences Corp.

Institutional & Insider Ownership

The shares of both Stellar Biotechnologies Inc. and Anavex Life Sciences Corp. are owned by institutional investors at 8.5% and 18.2% respectively. 1.4% are Stellar Biotechnologies Inc.’s share held by insiders. Insiders Competitively, held 5.17% of Anavex Life Sciences Corp. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Stellar Biotechnologies Inc. 4.46% 4.46% -17.02% -36.41% -84.95% -79.37%
Anavex Life Sciences Corp. -8.3% -17% -19.23% -48.53% -41.83% -34.78%

For the past year Anavex Life Sciences Corp. has weaker performance than Stellar Biotechnologies Inc.

Summary

On 5 of the 7 factors Stellar Biotechnologies Inc. beats Anavex Life Sciences Corp.

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein primarily in Europe, the United States, and Asia. It provides KLH, an immune-stimulating molecule used as an active pharmaceutical ingredient in various immunotherapies; and as an injectable product to assess immune response. The company offers its KLH protein under the Stellar KLH brand. Its products include Stellar KLH protein in various grades, formulations, and configurations for preclinical and clinical applications, as well as certain KLH-based in vitro diagnostic kits for preclinical use. The companyÂ’s customers and partners include multinational biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of AlzheimerÂ’s disease, other central nervous system diseases, pain, and various cancers. The companyÂ’s lead drug candidates include ANAVEX 2-73, a Phase 2a clinical trial for the treatment of AlzheimerÂ’s disease; and preclinical stage to treat ParkinsonÂ’s disease. Its preclinical drug candidates include ANAVEX 3-71, which uses ligands that activate sigma-1 and M1 muscarinic receptors to treat AlzheimerÂ’s disease; ANAVEX 1-41, a sigma-1 agonist that protects nerve cells from degeneration or death; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.